The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy and tolerability of bevacizumab (BEV) plus capecitabine and cisplatin (XP) in Chinese patients (pts) with locally advanced or metastatic gastric/gastroesophageal junction cancer (AGC): Results from the AVATAR study.
Lin Shen
No relevant relationships to disclose
Jin Li
No relevant relationships to disclose
Jian-Ming Xu
No relevant relationships to disclose
Hong-Ming Pan
No relevant relationships to disclose
Guanghai Dai
No relevant relationships to disclose
Shukui Qin
No relevant relationships to disclose
Liwei Wang
No relevant relationships to disclose
Jinwan Wang
No relevant relationships to disclose
Zhenzhou Yang
No relevant relationships to disclose
Shu Yongqian
No relevant relationships to disclose